239 related articles for article (PubMed ID: 26050556)
1. Herbs to curb cyclic nucleotide phosphodiesterase and their potential role in Alzheimer's disease.
Kumar A; Sharma V; Singh VP; Kaundal M; Gupta MK; Bariwal J; Deshmukh R
Mech Ageing Dev; 2015 Jul; 149():75-87. PubMed ID: 26050556
[TBL] [Abstract][Full Text] [Related]
2. Cyclic Nucleotides Signaling and Phosphodiesterase Inhibition: Defying Alzheimer's Disease.
Sharma VK; Singh TG; Singh S
Curr Drug Targets; 2020; 21(13):1371-1384. PubMed ID: 32718286
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential of phosphodiesterase inhibitors for cognitive amelioration in Alzheimer's disease.
Xi M; Sun T; Chai S; Xie M; Chen S; Deng L; Du K; Shen R; Sun H
Eur J Med Chem; 2022 Mar; 232():114170. PubMed ID: 35144038
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterases: Regulators of cyclic nucleotide signals and novel molecular target for movement disorders.
Sharma S; Kumar K; Deshmukh R; Sharma PL
Eur J Pharmacol; 2013 Aug; 714(1-3):486-97. PubMed ID: 23850946
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase inhibitors as a target for cognition enhancement in aging and Alzheimer's disease: a translational overview.
Heckman PR; Wouters C; Prickaerts J
Curr Pharm Des; 2015; 21(3):317-31. PubMed ID: 25159073
[TBL] [Abstract][Full Text] [Related]
6. PDE and cognitive processing: beyond the memory domain.
Heckman PR; Blokland A; Ramaekers J; Prickaerts J
Neurobiol Learn Mem; 2015 Mar; 119():108-22. PubMed ID: 25464010
[TBL] [Abstract][Full Text] [Related]
7. From Age-Related Cognitive Decline to Alzheimer's Disease: A Translational Overview of the Potential Role for Phosphodiesterases.
Heckman PRA; Blokland A; Prickaerts J
Adv Neurobiol; 2017; 17():135-168. PubMed ID: 28956332
[TBL] [Abstract][Full Text] [Related]
8. Modulation of Compartmentalised Cyclic Nucleotide Signalling via Local Inhibition of Phosphodiesterase Activity.
Brescia M; Zaccolo M
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27706091
[TBL] [Abstract][Full Text] [Related]
9. The Role of Phosphodiesterase-2 in Psychiatric and Neurodegenerative Disorders.
Zhang C; Lueptow LM; Zhang HT; O'Donnell JM; Xu Y
Adv Neurobiol; 2017; 17():307-347. PubMed ID: 28956338
[TBL] [Abstract][Full Text] [Related]
10. Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer's disease.
Prickaerts J; Heckman PRA; Blokland A
Expert Opin Investig Drugs; 2017 Sep; 26(9):1033-1048. PubMed ID: 28772081
[TBL] [Abstract][Full Text] [Related]
11. Phosphodiesterases in the central nervous system: implications in mood and cognitive disorders.
Xu Y; Zhang HT; O'Donnell JM
Handb Exp Pharmacol; 2011; (204):447-85. PubMed ID: 21695652
[TBL] [Abstract][Full Text] [Related]
12. Targeting cancer with phosphodiesterase inhibitors.
Savai R; Pullamsetti SS; Banat GA; Weissmann N; Ghofrani HA; Grimminger F; Schermuly RT
Expert Opin Investig Drugs; 2010 Jan; 19(1):117-31. PubMed ID: 20001559
[TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterase inhibition and modulation of corticostriatal and hippocampal circuits: Clinical overview and translational considerations.
Heckman PRA; Blokland A; Bollen EPP; Prickaerts J
Neurosci Biobehav Rev; 2018 Apr; 87():233-254. PubMed ID: 29454746
[TBL] [Abstract][Full Text] [Related]
14. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease.
Cheng J; Grande JP
Exp Biol Med (Maywood); 2007 Jan; 232(1):38-51. PubMed ID: 17202584
[TBL] [Abstract][Full Text] [Related]
15. Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret.
Duplantier AJ; Biggers MS; Chambers RJ; Cheng JB; Cooper K; Damon DB; Eggler JF; Kraus KG; Marfat A; Masamune H; Pillar JS; Shirley JT; Umland JP; Watson JW
J Med Chem; 1996 Jan; 39(1):120-5. PubMed ID: 8568798
[TBL] [Abstract][Full Text] [Related]
16. Opportunities and perspectives of small molecular phosphodiesterase inhibitors in neurodegenerative diseases.
Li Q; Liao Q; Qi S; Huang H; He S; Lyu W; Liang J; Qin H; Cheng Z; Yu F; Dong X; Wang Z; Han L; Han Y
Eur J Med Chem; 2024 May; 271():116386. PubMed ID: 38614063
[TBL] [Abstract][Full Text] [Related]
17. Sub-efficacious doses of phosphodiesterase 4 and 5 inhibitors improve memory in a mouse model of Alzheimer's disease.
Gulisano W; Tropea MR; Arancio O; Palmeri A; Puzzo D
Neuropharmacology; 2018 Aug; 138():151-159. PubMed ID: 29885420
[TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase inhibitors enhance object memory independent of cerebral blood flow and glucose utilization in rats.
Rutten K; Van Donkelaar EL; Ferrington L; Blokland A; Bollen E; Steinbusch HW; Kelly PA; Prickaerts JH
Neuropsychopharmacology; 2009 Jul; 34(8):1914-25. PubMed ID: 19262466
[TBL] [Abstract][Full Text] [Related]
19. Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer's Disease.
Wu Y; Li Z; Huang YY; Wu D; Luo HB
J Med Chem; 2018 Jul; 61(13):5467-5483. PubMed ID: 29363967
[TBL] [Abstract][Full Text] [Related]
20. The role of phosphodiesterase isoforms 2, 5, and 9 in the regulation of NO-dependent and NO-independent cGMP production in the rat cervical spinal cord.
de Vente J; Markerink-van Ittersum M; Vles JS
J Chem Neuroanat; 2006 Jun; 31(4):275-303. PubMed ID: 16621445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
